ArticleBioImpacts : BI2013
Intrinsic bio-signature of gene delivery nanocarriers may impair gene therapy goals.
Article in BioImpacts : BI, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Pleiotropic Properties of Amphiphilic Dihydropyridines, Dihydropyridones, and Aminovinylcarbonyl Compounds.Oxidative medicine and cellular longevity · 2020Article
- Effect of PEGylation on assembly morphology and cellular uptake of poly ethyleneimine-cholesterol conjugates for delivery of sorafenib tosylate in hepatocellular carcinoma.BioImpacts : BI · 2018Article
- Stimuli-responsive chitosan-based nanocarriers for cancer therapy.BioImpacts : BI · 2017Review
- Multifunctional mitoxantrone-conjugated magnetic nanosystem for targeted therapy of folate receptor-overexpressing malignant cells.Journal of nanobiotechnology · 2015Article
- Personalized cell-mediated immunotherapy and vaccination: combating detrimental uprisings of malignancies.BioImpacts : BI · 2015Article
- Bioimpacts of nanoparticle size: why it matters?BioImpacts : BI · 2015Article
- A prospective highlight on exosomal nanoshuttles and cancer immunotherapy and vaccination.BioImpacts : BI · 2015Article
- Surface modified multifunctional nanomedicines for simultaneous imaging and therapy of cancer.BioImpacts : BI · 2014Review
- Shikonin-loaded antibody-armed nanoparticles for targeted therapy of ovarian cancer.International journal of nanomedicine · 2014Article
- Targeting tumor microenvironment: crossing tumor interstitial fluid by multifunctional nanomedicines.BioImpacts : BI · 2014Review
- Impacts of quantum dots in molecular detection and bioimaging of cancer.BioImpacts : BI · 2014Review
- Dysregulated pH in Tumor Microenvironment Checkmates Cancer Therapy.BioImpacts : BI · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-viral lipid/polymeric vectors have widely been used as nanocarriers (NCs) for gene delivery. They possess large surface area to volume ratio and are able to interact with biomolecules through functional moieties, resulting in inadvertent biological impacts, in particular at genomic level. Thus, their genomic bio-signature needs to be investigated prior to use in vivo. Using high-throughput microarray and qPCR gene expression profiling techniques, we have reported the genomic impacts of lipid/polymeric NCs. Given the fact that the ultimate objectives of gene therapy may inevitably be impaired by nonspecific intrinsic genomic impacts of these NCs, here, we highlight their nonspecific genomic bio-signature. We envision that better understanding on the genotoxicity of gene delivery NCs, as guiding premise, will help us to develop much safer NCs and also to accelerate their translation into clinical use and to provide pivotal information on safety liabilities early in discovery and developments process prior to its inevitable consequences in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.